IRIS Accounts Production v26.1.10.61 10924881 director 1.9.24 31.8.25 31.8.25 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh109248812024-08-31109248812025-08-31109248812024-09-012025-08-31109248812023-08-31109248812023-09-012024-08-31109248812024-08-3110924881ns15:EnglandWales2024-09-012025-08-3110924881ns14:PoundSterling2024-09-012025-08-3110924881ns10:Director12024-09-012025-08-3110924881ns10:PrivateLimitedCompanyLtd2024-09-012025-08-3110924881ns10:SmallEntities2024-09-012025-08-3110924881ns10:AuditExempt-NoAccountantsReport2024-09-012025-08-3110924881ns10:SmallCompaniesRegimeForDirectorsReport2024-09-012025-08-3110924881ns10:SmallCompaniesRegimeForAccounts2024-09-012025-08-3110924881ns10:FullAccounts2024-09-012025-08-3110924881ns10:OrdinaryShareClass12024-09-012025-08-3110924881ns10:RegisteredOffice2024-09-012025-08-3110924881ns5:CurrentFinancialInstruments2025-08-3110924881ns5:CurrentFinancialInstruments2024-08-3110924881ns5:ShareCapital2025-08-3110924881ns5:ShareCapital2024-08-3110924881ns5:RetainedEarningsAccumulatedLosses2025-08-3110924881ns5:RetainedEarningsAccumulatedLosses2024-08-3110924881ns5:ComputerEquipment2024-09-012025-08-3110924881ns5:ComputerEquipment2024-08-3110924881ns5:ComputerEquipment2025-08-3110924881ns5:ComputerEquipment2024-08-3110924881ns5:WithinOneYearns5:CurrentFinancialInstruments2025-08-3110924881ns5:WithinOneYearns5:CurrentFinancialInstruments2024-08-3110924881ns10:OrdinaryShareClass12025-08-31
REGISTERED NUMBER: 10924881 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 August 2025

for

Mike Dawson Antimicrobial Research
Consultancy Limited

Mike Dawson Antimicrobial Research
Consultancy Limited (Registered number: 10924881)

Contents of the Financial Statements
for the Year Ended 31 August 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Mike Dawson Antimicrobial Research
Consultancy Limited

Company Information
for the Year Ended 31 August 2025







DIRECTOR: Mr Michael Dawson





REGISTERED OFFICE: Unit 1 The Cam Centre
Wilbury Way
Hitchin
Hertfordshire
SG4 0TW





REGISTERED NUMBER: 10924881 (England and Wales)






Mike Dawson Antimicrobial Research
Consultancy Limited (Registered number: 10924881)

Balance Sheet
31 August 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 5 250 624

CURRENT ASSETS
Debtors 6 3,113 4,612
Cash at bank 87,247 60,589
90,360 65,201
CREDITORS
Amounts falling due within one year 7 8,803 9,328
NET CURRENT ASSETS 81,557 55,873
TOTAL ASSETS LESS CURRENT LIABILITIES 81,807 56,497

PROVISIONS FOR LIABILITIES 47 119
NET ASSETS 81,760 56,378

CAPITAL AND RESERVES
Called up share capital 8 100 100
Retained earnings 81,660 56,278
SHAREHOLDERS' FUNDS 81,760 56,378

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 6 November 2025 and were signed by:





Mr Michael Dawson - Director


Mike Dawson Antimicrobial Research
Consultancy Limited (Registered number: 10924881)

Notes to the Financial Statements
for the Year Ended 31 August 2025


1. STATUTORY INFORMATION

Mike Dawson Antimicrobial Research Consultancy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared using the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Judgements
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Turnover
Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 25% on cost

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Mike Dawson Antimicrobial Research
Consultancy Limited (Registered number: 10924881)

Notes to the Financial Statements - continued
for the Year Ended 31 August 2025


3. ACCOUNTING POLICIES - continued

Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits.

Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends
Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2024 - 1 ) .

5. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 September 2024
and 31 August 2025 2,549
DEPRECIATION
At 1 September 2024 1,925
Charge for year 374
At 31 August 2025 2,299
NET BOOK VALUE
At 31 August 2025 250
At 31 August 2024 624

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
VAT - 1
Prepayments and accrued income 3,059 4,559
Prepayments 54 52
3,113 4,612

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 240 228
Tax 7,184 7,645
Directors' current accounts 59 205
Accrued expenses 1,320 1,250
8,803 9,328

Mike Dawson Antimicrobial Research
Consultancy Limited (Registered number: 10924881)

Notes to the Financial Statements - continued
for the Year Ended 31 August 2025


8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
100 Ordinary 1 100 100

9. RELATED PARTY TRANSACTIONS

At the balance sheet date, the company owed £59 (2024: £205) to Michael Dawson. There are no terms relating to the payment of interest or repayment of capital on this loan.

10. ULTIMATE CONTROLLING PARTY

The controlling party is Mr Michael Dawson.